investigation of the inhibition activity of aluminium oxide nanoparticles for herpes simplex type 1

several studies have shown that herpes simplex type 1 )hsv-1 (is one of the viruses resistant to medications, so potential antiherpetic agents need to be evaluated. this study aimed to evaluate the impact of aluminum oxide nanoparticles (al2o3-nps) on hsv-1 infection. characterization of al2o3-nps was performed using field emission scanning electron microscopy (fesem), x-ray diffraction (xrd), dynamic light scattering (dls), and high-resolution transmission electron microscopy (hrtem). the mtt test was used to investigate the toxicity action of al2o3-nps on viable cells. quantitative real-time pcr (qrt-pcr)and tcid50 assays were used to achieve the antiherpetic performance al2o3-nps.indirect immunofluorescence assay (ifa) was performed to determine the inhibitory impact of al2o3-nps on viral antigen expression, and acyclovir was utilized as a standard agent in all tests. hsv-1 subjected to al2o3-nps at the maximum non-toxic concentration (100 μg / ml) leads to a decrease of 0.1, 0.7, 1.8, and 2.5 log10 tcid50 in the infectious titer relative to virus control (p 0.0001). this concentration of al2o3-nps was correlated with 16.9%, 47.1 %, 61.2 %, 72.5 % and 74.6 % inhibition rates, calculated based on hsv-1 viral load compared to virus control. our results have shown that al2o3-nps have a robust antiviral activity against hsv-1. this function demonstrates excellent potential for using al2o3-np in topical formulations for treating orolabial or genital herpetic lesions.